CARSTEN BOESS
CIK 1277495 · SVP, Chief Financial Officer · last filed 2026-07-06
CARSTEN BOESS is a SVP, Chief Financial Officer who has filed 54 SEC Form 4 insider transactions across 8 companies since 2007. The most recent filing, for RCKT, was dated Jul 6, 2026. Across all open-market trades the lifetime net is −$17.0M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $9.7M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$9.74M
8
54
-$16.98M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| RCKT | Director | 52,862 | $3.14 | $166.0K | $0 | 6 | 2026-07-06 |
| Avidity Biosciences, Inc. (RNAM) Delisted | Director | 0 | — | — | $0 | 1 | 2026-02-27 |
| RCKTW | Director | 30,000 | $0.00 | $99 | $0 | 3 | 2025-07-18 |
| RNA | Director | 6,692 | $11.49 | $76.9K | $0 | 5 | 2025-06-12 |
| KNSA | 10%+ Owner | 79,589 | $79.44 | $6.32M | $0 | 1 | 2018-05-29 |
| ROCKET PHARMACEUTICALS, INC. (ITEK) Delisted | Director | — | — | — | $0 | 3 | 2017-06-21 |
| SYNAGEVA BIOPHARMA CORP (GEVA) Delisted | SVP, Chief Financial Officer | 0 | — | — | -$12.17M | 17 | 2015-06-23 |
| PODD | Vice President, International | 18,941 | $167.47 | $3.17M | -$4.81M | 16 | 2011-04-27 |
Recent Filings
54 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-07-06 | RCKT | Grant (A) | +22,862 | $0 | EDGAR |
| 2026-03-02 | — | Grant (A) | — | $0 | |
| 2026-02-27 | Avidity Biosciences, Inc. (RNAM) Delisted | Disp (D) | −6,692 | $0 | EDGAR |
| 2025-07-18 | RCKTW | Grant (A) | +30,000 | $0 | EDGAR |
| 2025-06-12 | RNA | Grant (A) | +6,692 | $0 | EDGAR |
| 2025-02-06 | — | Notice (144) | −25,000 | -$34.0K | EDGAR |
| 2024-06-20 | RCKTW | Grant (A) | — | $0 | EDGAR |
| 2024-06-14 | RNA | Grant (A) | — | $0 | EDGAR |
| 2023-06-26 | RCKTW | Grant (A) | — | $0 | EDGAR |
| 2023-06-20 | RNA | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.